Trial · NCT00042939
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria) | Arm A: Irinotecan/Docetaxel | 0.045 | 90% Confidence Interval 0.015 to 0.184 | Proportion of participants | |
| Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria) | Arm B: Irinotecan/Docetaxel/Cetuximab | 0.07 | 90% Confidence Interval 0.024 to 0.198 | Proportion of participants | |
| Progression-free Survival | Arm A: Irinotecan/Docetaxel | 3.9 | 90% Confidence Interval 2.4 to 5.0 | months | |
| Progression-free Survival | Arm B: Irinotecan/Docetaxel/Cetuximab | 4.5 | 90% Confidence Interval 2.7 to 5.6 | months | |
| Overall Survival | Arm A: Irinotecan/Docetaxel | 6.5 | 90% Confidence Interval 5.6 to 9.9 | months | |
| Overall Survival | Arm B: Irinotecan/Docetaxel/Cetuximab | 5.3 | 90% Confidence Interval 4.5 to 9.4 | months | |
| Epidermal Growth Factor Receptor (EGFR) Status | Arm A: Irinotecan/Docetaxel | Positive | 29 | participants | |
| Epidermal Growth Factor Receptor (EGFR) Status | Arm B: Irinotecan/Docetaxel/Cetuximab | Positive | 30 | participants | |
| Epidermal Growth Factor Receptor (EGFR) Status | Arm A: Irinotecan/Docetaxel | Negative | 1 | participants | |
| Epidermal Growth Factor Receptor (EGFR) Status | Arm B: Irinotecan/Docetaxel/Cetuximab | Negative | 1 | participants | |
| Proportion of Patients With Thromboembolic Events | Arm A: Irinotecan/Docetaxel | 0 | 90% Confidence Interval 0.0 to 0.066 | Proportion of participants | |
| Proportion of Patients With Thromboembolic Events | Arm B: Irinotecan/Docetaxel/Cetuximab | 0.023 | 90% Confidence Interval 0.001 to 0.106 | Proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00042939/results